Clinical trial · Interventional
The Application Value of Spectral CT in the Accurate Staging of Colorectal Cancer
NCT06977373CI-TRIAL-00089888not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Spectral CT was used to prospectively collect medical images and clinical data related to colorectal cancer, evaluate the effect of image quality in the diagnosis of colorectal cancer, and evaluate the application value in the accurate staging of colorectal cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| To explore the value of spectral CT in the diagnosis and treatment of colorectal cancer | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- The application value of spectral CT in the accurate staging of colorectal cancer
- description
- Prospectively collect medical images and clinical data related to colorectal cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accurate staging of colorectal cancer.Patients diagnosed with colorectal cancer in Yunnan Provincial Cancer Hospital from April 2025 to May 2026 were consecutively included, and after scanning with Philips Quark CT, the TNM stage of colorectal cancer patients was assessed by two radiologists, and finally statistical analysis was performed.
- interventionNames
- Diagnostic Test: To explore the value of spectral CT in the diagnosis and treatment of colorectal cancer
Primary outcomes (1)
- measure
- Pathological TNM staging
- timeFrame
- 1 day
- description
- Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment. 2. Age \> 18 years. 3. Patients suspected of having colorectal cancer. 4. Patients who have signed the informed consent form. Exclusion Criteria: 1. Severe cardiac, pulmonary, or renal insufficiency. 2. Allergy to iodine-based contrast agents. 3. Inability to cooperate with the CT examination. 4. Poor image quality of the Quark Spectral CT scan. 5. Women who are pregnant or breastfeeding.
References
Publications (0)
Data not yet available
No reference posted for this study.